Background and Purpose-Hypertension is the most important risk factor for intracerebral hemorrhage (ICH), but further characterization is needed for groups at high risk of ICH. One way to predict the risk of developing a disease is with plasma biomarkers. This study aimed to investigate the association between the biomarker, D-dimer, and ICH risk. Methods-This population-based, nested case-control study was conducted using data from 2 population-based surveys;
I
ntracerebral hemorrhage (ICH) accounts for ≈10% of all strokes in Sweden. Moreover, ICH is associated with high rates of death and disability. 1, 2 The incidence of ICH has not decreased over time. 2 Therefore, it is essential to find strategies for preventing ICH. Identifying high-risk groups is an important first step in targeted prevention programs. Hypertension is the most important known risk factor for ICH; individuals with hypertension have >4-fold increased risk of developing ICH compared with normotensive individuals. 3 However, we need further characterization of groups that are at high risk of ICH. One way of predicting the risk of developing a disease is with biomarkers. Several biomarkers related to coagulation, fibrinolysis, and inflammation have been studied in association with the risk of ICH. [4] [5] [6] [7] [8] [9] [10] Recently, D-dimer was suggested as a potential biomarker for ICH. 11 D-dimer is a product of fibrin degradation. It reflects ongoing coagulation and fibrinolytic processes that can vary over time. 12 These processes might correlate with the degree of vessel injury. High D-dimer concentrations have been shown to be associated with both cardiovascular events [13] [14] [15] and major bleeding during warfarin treatment. 13 Only a few studies have evaluated D-dimer as a risk marker for hemorrhagic stroke. The Italian EPICOR study (European Prospective Investigation Into Cancer and Nutrition -Italy Cohort) showed an association between high concentrations of D-dimer and hemorrhagic stroke; however, that finding was not supported by findings in the French 3C (ThreeCity) study or the American ARIC (Atherosclerosis Risk in Communities) study. 8, 9, 11 D-dimer levels are affected by acute phase reactions, which are triggered by acute medical conditions, such as stroke. Therefore, studies where the blood samples are collected before the ICH event are needed to evaluate D-dimer as a risk marker for ICH. 16 The fact that D-dimer concentrations are correlated with cardiovascular risk factors must be taken into consideration when studying D-dimer as a biomarker. 17 Consequently, it is important to have reliable information on the presence of cardiovascular risk factors in the study population, when investigating the association between D-dimer and ICH. Accordingly, to elucidate the relationship between D-dimer levels and ICH, studies where blood samples and information about cardiovascular risk factors are collected before the ICH event are warranted. Our hypothesis was that high concentrations of D-dimer are associated with increased risk of ICH.
This study aimed to investigate the association between D-dimer levels and ICH in a population-based, case-control study.
Methods
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The data sets generated and analyzed during the current study are not publicly available, because of restrictions set in the ethics approval. However, they can be available, on reasonable request, from the corresponding author. This study was approved by the Regional Ethics Review Board, Umeå, Sweden. All study participants provided written informed consent. All procedures followed were in accordance with institutional guidelines.
Study Population
This study was conducted as a nested, case-control study in 2 settings-the Västerbotten Intervention Programme and the Northern Sweden MONICA survey (Monitoring Trends and Determinants in Cardiovascular Disease). Between 1985 and March 2007, 98 625 unique inhabitants of northern Sweden had participated in one of these surveys. All participants underwent a health examination and blood sampling at baseline. Cases were defined as participants that were diagnosed with a definite first-ever ICH, between 1985 and March 2007. All cases underwent health examination and blood sampling before the ICH event. Controls from the same population were matched to each case with ICH.
In the Västerbotten Intervention Program, beginning in 1985, the inhabitants of Västerbotten County in northern Sweden (population ≈260 000 inhabitants), were invited to participate in a health examination at 30, 40, 50, and 60 years of age. Health examinations were performed at the participant's primary healthcare center. 18 The participation rate in the Västerbotten Intervention Program ranged between 56% and 65%. 19 In the present study, 96% of participants underwent a health examination in the Västerbotten Intervention Program.
The Northern Sweden MONICA survey was a population-based study of cardiovascular disease and diabetes mellitus conducted in Västerbotten and Norrbotten counties, the 2 northernmost counties of Sweden. In MONICA, 2000 to 2500 randomly selected inhabitants, aged 25 to 74 years, were invited to participate in each survey (surveys were performed in the years 1986, 1990, 1994, 1999, and 2004) . 20 The participation rate was between 71% and 81%.
21
Measurements and Definitions
The health examinations and questionnaires used in the 2 settings have been previously described. 18, 20 Briefly, participant height and weight were measured in light clothing. Body mass index was calculated as the weight (kg) divided by the square of the height (m 2 ). Blood pressure was measured after resting at least 5 minutes. 22 Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or self-reported use of antihypertensive treatment during the 2 weeks preceding the health survey.
Serum samples for cholesterol measurements were obtained after fasting at least 4 hours. 23 Total cholesterol was measured at a hospital laboratory or at the primary healthcare centers. Diabetes mellitus was defined as self-reported use of antidiabetic drugs, a fasting plasma glucose ≥7.0 mmol/L, or a 2-hour oral glucose tolerance test value ≥11.1 mmol/L, in venous blood samples, or ≥12.2 mmol/L, in capillary blood samples. 24, 25 Data on smoking were collected with a questionnaire. Smokers were divided into daily smokers and nonsmokers. Previous smokers and occasional smokers were classified as nonsmokers.
Venous blood samples were drawn into Venoject tubes containing 1/100 volume of 0.5 mmol/L EDTA after fasting for at least 4 hours and after resting for 5 minutes with minimum stasis. The samples were centrifuged at 1500g for 15 minutes, then they were aliquoted and stored at −80°C, until analysis. Blood samples from cases and corresponding controls were analyzed together, but the positions of the 1 case and 2 control samples were varied randomly. The laboratory staff were blinded to the case/control identities of samples. D-dimer contents were analyzed with an ELISA method (ab196269, Abcam) and the coefficient of variation was 3% (intra-assay).
Case Ascertainment
Individuals with a first-ever ICH between 1985 and 2007 were identified in the Northern Sweden MONICA incidence registry, where all stroke events are registered for inhabitants of northern Sweden, aged 25 to 74 years. The registry included only individuals with ICH, confirmed with a computed tomographic scan or autopsy, and without concomitant brain tumor, trauma, or severe blood disease. Individuals with subarachnoid hemorrhage or previous stroke were excluded from our study.
Controls
For each individual with ICH, we selected 2 controls, matched for sex, age ±2 years, health examination date ±1 year, health examination setting, and geographical region. Controls were excluded if they died, moved out of the study region, or experienced a stroke, according to the Northern Sweden MONICA incidence registry, before the date of the index ICH.
Statistical Analysis
Baseline characteristics are expressed as the number of observations and percentage or the median and interquartile range. Differences between groups were assessed with the Mann-Whitney U test for continuous variables and the χ 2 test for categorical variables. Spearman rank-order correlation was used to test correlations between D-dimer levels and traditional cardiovascular risk factors. P values <0.05 (2-sided) were considered significant.
The D-dimer concentration was analyzed as both a continuous variable, per SD, and a categorical variable in tertiles. Tertiles boundaries were based on the D-dimer concentrations of the controls.
Univariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% CIs to evaluate associations between D-dimer levels and risk of ICH. Multivariable conditional logistic regression analyses were adjusted for hypertension, body mass index, cholesterol, diabetes mellitus, and smoking because these risk factors were considered potential confounders. We also performed an additive interaction analysis to test for an interaction between D-dimer levels and hypertension.
We stratified the cases and controls into 3 groups based on time from blood sampling to ICH event. Each time stratum included an equal number of cases and controls. This was done to test the association between D-dimer concentrations and risk of ICH in each time stratum.
A sample size calculation indicated that an OR of 2.0 could be detected with a power of 80% and a significance level of 0.05 (2-sided) for an increased risk of ICH in individuals with the highest tertile of D-dimer when including 137 cases and at least 1 matched control for each case.
All statistical analyses were performed with IBM SPSS Statistics for Macintosh, Version 24.0 (IBM Corp, Armonk, NY).
Missing Values
Only cases and controls with complete data on the variables D-dimer, hypertension, body mass index, cholesterol, diabetes mellitus, and smoking were included (complete cases analysis). Because of this
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restriction, a total of 38 cases were excluded because of missing values, leading to the inclusion of a total of 141 cases with ICH.
Results
This study included 141 cases and 255 controls. A flowchart of the study population is shown in Figure 1 , and the baseline characteristics are shown in Table 1 . The median participant age was 60 years, and 39% were women. Individuals with ICH exhibited significantly higher median values of blood pressure, body mass index, diabetes mellitus prevalence, and D-dimer concentrations, compared with controls. The median time-to-event was 5.2 years (range, 0.04-15.9 years). Correlations between D-dimer levels and age, sex, and traditional cardiovascular risk factors are shown in Table 2 . D-dimer concentrations were positively correlated with age, female sex, systolic blood pressure, diastolic blood pressure, hypertension, and body mass index. The association between D-dimer concentrations and firstever ICH are presented in Table 3 . In a univariable conditional logistic regression analysis, with D-dimer as a continuous variable, we found an association between D-dimer concentrations and ICH (OR, 1.41 per SD; 95% CI, 1.12-1.77). For the D-dimer tertiles, we found an association between the highest tertile of D-dimer and ICH (OR, 2.38; 95% CI, 1.34-4.21); with the lowest tertile as reference.
In a multivariable model adjusted for hypertension, body mass index, cholesterol levels, diabetes mellitus, and smoking, the association between D-dimer concentrations (as a continuous variable) and ICH remained significant (OR, 1.36 per SD; 95% CI, 1.05-1.77). There was a significant association between tertiles of D-dimer and ICH (P for trend=0.03) in the adjusted model. There was no significant additive interaction between D-dimer levels and hypertension (data not shown).
Furthermore, when we stratified the cases and controls in 3 groups according to time from blood sampling at health examination to ICH event, we found that the association between D-dimer levels and ICH in a multivariable model was most pronounced in individuals with the shortest time from blood sampling to event (<3.5 years; OR, 1.78; 95% CI, 1.05-3.05 per SD of D-dimer; Figure 2 ).
Discussion
This matched case-control study found a significant association between baseline D-dimer concentrations and the risk of ICH. This association remained significant after adjusting for cardiovascular risk factors.
Previously, the prospective EPICOR study showed an association between D-dimer levels and hemorrhagic Values represent the median (interquartile range) or n (%). BMI indicates body mass index; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
*Hypertension was defined as SBP ≥140 mm Hg, DBP ≥90 mm Hg, or antihypertensive treatment.
†Diabetes mellitus was defined as pharmacologically treated diabetes mellitus, fasting plasma glucose ≥7.0 mmol/L, or 2-hour oral glucose tolerance test value ≥11.1 mmol/L (venous blood samples) or ≥ 12.2 mmol/L (capillary blood samples). stroke, with hazard ratios comparable to the ORs found in our study. 11 Conversely, the previous ARIC and 3C studies found no association between D-dimer levels and future ICH. However, only 21 individuals with hemorrhagic stroke were included in the 3C study; thus, the risk of a type II error was substantial. 9 Hypertension is the most important risk factor for ICH. Long-standing hypertension may cause changes in small brain vessels, making them more prone to rupture. In turn, these changes could activate the coagulation and fibrinolytic systems, and consequently, give rise to elevated D-dimer levels. According to this hypothesis, plasma D-dimer concentrations would increase close to the ICH event. This hypothesis was consistent with our finding that the association between D-dimer levels and ICH was strongest in the cases with the shortest time from blood sampling at health examination to ICH. Moreover, this hypothesis might explain the lack of association between D-dimer levels and hemorrhagic stroke in the ARIC study, where the median follow-up time was 8.5 years (Folsom, unpublished data, 2017) .
Study Strengths
In our study, blood samples were collected before the ICH event which eliminated the risk that D-dimer concentrations might be affected by the acute phase reaction triggered by the ICH. The study was population-based, with a high participation rate. The characteristics of participants of the Västerbotten Intervention Programme and MONICA Northern Sweden surveys have been shown to be similar to those of nonparticipants in the population. 19, 26 The study included extensive baseline health examinations, where all participants were evaluated for the presence of cardiovascular risk factors. This enables adjustments for potential confounders. Matching controls and cases from the same study population minimized the risk of a selection bias among controls. 27, 28 Finally, our study design ensured that cases and controls had similar follow-up durations and that samples were stored for similar time periods.
Limitations
The main limitation of our study was the limited number of ICH cases, but the number of ICH cases included in this study was 1.5-fold greater than the number included in the next largest study published previously on this topic. 8 Our finding of an association between D-dimer and risk of ICH should be replicated in a future study, including a sufficient number of ICH cases with a short time between blood sampling and ICH event, aiming to find an optimal D-dimer cutoff level.
In our study, we only included individuals that experienced ICH before the age of 75 years, and the vast majority of the study participants were white. Thus, our results cannot be generalized to ICH in older individuals or to other ethnic groups. D-dimer levels were measured at only 1 time point, which increased the risk of underestimating the association between the risk marker and the outcome. 29 A previous study showed that repeated measurements of D-dimer would optimize the validity coefficient.
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Conclusions
High plasma concentrations of D-dimer were associated with increased risk of a future ICH, after adjusting for cardiovascular risk factors. This association was predominantly driven by the cases with the shortest time from blood sampling to ICH event.
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